Current Rheumatology Reports

, Volume 7, Issue 2, pp 87–93

Outcomes and disease activity measures for assessing treatments in the idiopathic inflammatory myopathies

Authors

  • Chester V. Oddis
    • Division of Rheumatology and Clinical ImmunologyUniversity of Pittsburgh School of Medicine
Article

DOI: 10.1007/s11926-005-0059-y

Cite this article as:
Oddis, C.V. Curr Rheumatol Rep (2005) 7: 87. doi:10.1007/s11926-005-0059-y

Abstract

The assessment and treatment of patients with idiopathic inflammatory myopathy has taken a major step forward over the past few years. Through the efforts of multi-disciplinary international groups of experts interested in the management of patients with myositis, initiatives have led to the development of a core set of outcome measures critical to their assessment. Similarly, the lack of consensus on several issues of clinical trial design has been addressed resulting in the development of a definition of clinical improvement for adult and juvenile patients with inflammatory myopathy using the core set outcomes. The final step in the puzzle of well-designed therapeutic trials in myositis is the determination of consensus guidelines to conduct such trials in adult and pediatric populations of myositis patients.

Copyright information

© Current Science Inc 2005